drugset / Trial / NCT02117076

Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome

NCT02117076

Phase 4 Terminated 5 enrolled Theresa Zesiewicz, MD
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study will compare the safety, effectiveness and tolerability of gabapentin (Neurontin) versus gabapentin enacarbil (Horizant) as treatment restless leg syndrome.

Timeline

Start
2014-04
Primary completion
2016-06
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Gabapentin Small molecule 1200 mg
Comparator gabapentin enacarbil Small molecule 1200 mg